Cancer Immunology Immunotherapy
Source
ISSNs 0340-7004, 1432-0851
Source type: journal
Publisher: Springer Science+Business Media
Alternate names Cancer immunology, immunotherapy (Print), CII. Cancer immunology and immunotherapy
Fully open access: No
In DOAJ: No
Article Processing Charge: $4,390
2yr mean citedness: 5.276
H-index: 156
I10-index: 4,564
Works count: 6,586
Citations count: 215,800
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy
2008 · C. Marcela Díaz‐Montero, Mohamed L. Salem, et al. · Cancer Immunology Immunotherapy
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
2006 · François Ghiringhelli, Cédric Menard, et al. · Cancer Immunology Immunotherapy
An immune-active tumor microenvironment favors clinical response to ipilimumab
2011 · Rui‐Ru Ji, Scott D. Chasalow, et al. · Cancer Immunology Immunotherapy